Navigation Links
Xenon Announces Appointment of EVP, Research & Development
Date:2/13/2013

VANCOUVER, British Columbia, Feb. 13, 2013 /PRNewswire/ -- Xenon Pharmaceuticals Inc. is pleased to announce the appointment of Gary J. Bridger PhD as Executive Vice President, Research and Development.

"We are delighted to welcome Gary to the Xenon team," commented Simon Pimstone , Xenon's President and CEO. "As a co-founder and CSO of AnorMED, he was responsible for the development of MOZOBIL, a hematopoietic stem cell mobilizing agent for non-Hodgkin's lymphoma and multiple myeloma patients, from discovery through completion of phase III trials.  Having also held an executive position at Genzyme, Gary will bring a unique experience to Xenon of small and large public biotech and orphan drug development. I am confident that Gary will make many major contributions to Xenon's future growth."

Dr. Bridger has spent over 20 years in the life sciences industry including positions at Johnson Matthey, AnorMED and Genzyme. Dr. Bridger was a primary member of the team that managed AnorMED's acquisition by Genzyme for US$580 million. Prior to joining Xenon he was a partner with Ventures West Capital Management and he currently serves on the Scientific Advisory Board of Alectos Pharmaceuticals. Dr. Bridger received his PhD in Organic Chemistry from the University of Manchester UK and completed a post-doctoral fellowship at Boston College.  He is the co-author of more than 90 peer-reviewed publications and 40 granted US patents, mainly in the field of chemokine receptor antagonists.

About Xenon Pharmaceuticals Inc. Xenon is a privately owned, clinical genetics-based drug discovery and development company engaged in developing novel therapies for rare diseases. For more information, visit the Company's website at http://www.xenon-pharma.com.

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.


'/>"/>
SOURCE Xenon Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BiOptix announces expansion of Innovators Program at Molecular Med TRI-CON 2013
2. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
3. OrbusNeich Announces Favorable Ruling From the European Patent Office
4. Trovagene Announces Commercial Launch Timelines for HPV Carrier and Oncogene Mutation Tests
5. Comprehensive Care Corporation Announces New Medicare Contract with Humana Health Plan of California, Inc.
6. Unilife Corporation Announces Financial Results For Fiscal Year 2013 Second Quarter
7. Regeneron Announces Receipt of Hart-Scott-Rodino Notice
8. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
9. Depomed Announces Appointment of Vicente J. Anido, Jr., Ph.D. to Board of Directors, and Retirement of Directors Julian N. Stern and Craig R. Smith, M.D.
10. CPhI Announces its 2nd Annual Global Pharma Regulatory Summit
11. Imprimis Pharmaceuticals Announces Pricing of Public Offering of 1,840,000 Shares of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2017)... AirXpanders, Inc. (ASX: AXP) (AirXpanders or Company), ... sale and distribution of the AeroForm® Tissue Expander System, ... commercial roll-out in the United States ... hundred (100) medical institutions and health systems, located throughout ... alternative for women who choose reconstructive surgery following a ...
(Date:6/8/2017)... June 8, 2017   Responding to Heath Ledger,s ... the death of singer Chris Cornell in May, ... International offers a free online psychiatric drug ... and families about psychotropic drug risks. The ... died from an accidental overdose, has called for tighter rules ...
(Date:6/7/2017)... , June 7, 2017  Novavax, Inc., (Nasdaq: ... two Phase 2 trials of its RSV F protein recombinant ... bearing age have been published in the journal ... been shared in prior scientific conferences). The Company previously announced ... 2014. Novavax is developing the RSV F Vaccine with the ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... , ... Goodcents Deli Fresh Subs today announced the opening of a new ... St. Topeka, Kan. 66604 (near 21st and Gage). It is owned and operated by ... locations in the Topeka and Bonner Springs, Kan. area. , “Goodcents has such ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ensuring meat products have reached ... the importance of correctly using a meat thermometer. The videos feature University of ... on consumer food safety habits. Dr. Bruhn explains the variety of meat thermometers ...
(Date:6/23/2017)... , ... June 23, 2017 , ... 21 Middle East ... (EF) has selected 21 leaders from government, business and civil society in 11 countries ... the U.S. this fall, engaging in a transformative exchange of knowledge and ideas with ...
(Date:6/23/2017)... ... June 23, 2017 , ... PureLife Dental is pleased to announce that California ... members. As part of the amalgam separator endorsement, all CDA members may purchase an ... off the retail value. This partnership between PureLife and CDA is especially timely as ...
(Date:6/23/2017)... ... June 23, 2017 , ... American Farmer, will feature ... which is slated to air fourth quarter 2017. American Farmer airs Tuesdays at 8:30aET ... a Danish pharmacist, founded Chr. Hansen in Denmark in 1874 after a groundbreaking discovery ...
Breaking Medicine News(10 mins):